A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 11 Sep 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 27 Apr 2025 to 11 May 2023.
- 13 Feb 2021 Results assessing efficacy and safety of combination of sitravatinib and nivolumab in patients with locally-advanced clear cell renal cell carcinoma, presented at the 2021 Genitourinary Cancers Symposium.